FDA Approves Treatment for for Chronic Immune Thrombocytopenia
April 19th 2018Officials with the FDA have approved fostamatinib disodium hexahydrate (Tavalisse, Rigel) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
Read More